

**For more information contact:**

Emily Kielthy

media@nanospherehealth.com

646-695-7045



## **NanoSphere Health Sciences' Brand Evolve Formulas Expanding Rapidly Across Colorado and Beyond**

*Next-Generation Cannabis Products Now Available in Over 200 Colorado Dispensaries, with  
Production Beginning in the California Market*

DENVER (July 11, 2018)— [NanoSphere Health Sciences INC](#) (CSE: NSHS) (OTC: NSHSF), the biotech firm behind the groundbreaking NanoSphere Delivery System™, is experiencing a period of rapid growth for its cannabis brand, Evolve Formulas. The company has not only successfully expanded the product line to over 200 dispensaries in the Colorado market, but has also officially begun training and preparation for production in the California market.

Propelling this accelerated growth is Evolve Formulas' pioneering product, Transdermal NanoSerum™; a viscous gel which is applied to the skin for rapid and effective relief from pain, inflammation and anxiety. The rate of growth has been shown to be roughly 30% month over month in demand for NanoSerum™, allowing NanoSphere Health Sciences to discuss significant sales revenues for the first time since becoming publicly listed in December 2017.



Evolve Formulas products utilize the patented NanoSphere Delivery System™ to nanoencapsulate cannabinoids in lipid membranes for transportation through the skin and mucosa into the cells and bloodstream. This technology eliminates delayed onset of action, vastly increases bioavailability of the ingredients and alleviates adverse side effects of cannabis.

The NanoSphere Health Sciences business model is centered on licensing IP to allow the expansion of Evolve Formulas into new legal markets. Having recently announced a licensing partnership with Vertical™, the largest fully integrated company in the U.S. cannabis market, for multiple states, NanoSphere Health Sciences has now initiated partner training in California for the production of its products and unique technology and has started transporting essential equipment to new manufacturing sites.

“We are now in roughly one of every four stores in Colorado—an impressive rate of penetration into a highly competitive market. This, coupled with countless powerful testimonials we have received from Evolve Formulas customers—who rely on our products to relieve everything from chronic pain to PTSD—demonstrates our company’s superior offerings. We are also excited to be officially in the first

stage of our California journey by commencing production in this new market, so that we can bring the benefits of cannabis to even more consumers in a safer, more effective way,” said David Sutton, COO and President of NanoSphere Health Sciences and Evolve Formulas.

[A full list of dispensaries in Colorado carrying Evolve Formulas products can be found here.](#)

For more information or to schedule an interview, please contact Emily Kielthy at [media@nanospherehealth.com](mailto:media@nanospherehealth.com) or 646-695-7045.

###

### **On behalf of the Board**

Robert Sutton, CEO and Chairman

Office: 720.520.4283

Email: [rsutton@nanospherehealth.com](mailto:rsutton@nanospherehealth.com)

### **Investor Contact:**

Victor Goncalves, Executive Vice President

Mobile: 204-997-5517

E-mail: [vgoncalves@nanospherehealth.com](mailto:vgoncalves@nanospherehealth.com)

### **NanoSphere’s Commitment to Licensing IP**

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: <https://www.nanospherehealth.com/licensing/>

### **About NanoSphere**

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit <http://www.nanospherehealth.com>.

### **About Evolve Formulas**

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis,

pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit <https://www.evolveformulas.com/>. Follow us on [Facebook](#), [Instagram](#) and [Twitter](#).

*The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.*

#### **Forward Looking Statement Caution**

*This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.*